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        Immunological tolerance ensures proper discrim-
ination of self from nonself by the immune sys-
tem. Despite extensive pruning of diff  erentiating 
thymocytes to eliminate self-reactive specifi  c-
ities, potentially self-destructive cells do escape 
into the periphery, necessitating the mobiliza-
tion of peripheral regulatory mechanisms to pre-
vent autoimmunity (  1  ). One such mechanism 
is the suppressive action of a particular lineage 
of T reg cells (  2  ) that expresses the winged-
helix/forkhead transcription factor Foxp3, rou-
tinely comprising 5  –  10% of CD4  +   T cells in 
normal, unmanipulated individuals (  3  ). The criti-
cal role of Foxp3 in T reg cells is evident in 
the lymphoproliferative disorder and multi-
organ autoimmunity accompanying defi  ciencies 
in this molecule both in humans and mice (  4  ). 
Furthermore, ectopic expression of Foxp3 is 
suffi   cient, in certain experimental settings, to im-
part suppressive function to conventional CD4  +   
(Tconv) cells (  5  ). However, more recent data 
have provided a revised view of the suffi   ciency 
of and necessity for Foxp3 in the generation 
and sustenance of the T reg lineage (  6  –  8  ). 
  CD4  +  Foxp3  +   cells diff  erentiate in the thy-
mus and may also be generated in the periphery 
by antigen-driven conversion of naive Tconv 
cells under certain conditions (for review see 
reference   9  ). In addition, in vitro activation of 
peripheral CD4  +  CD25        T cells in the presence 
of TGF-     and IL-2 induces Foxp3 expression 
and conversion to T reg cells in various model 
systems (  10, 11  ). More recent evidence indi-
cates that even though TGF-     is not critical for 
thymic generation of T reg cells, this factor is 
important for maintenance of the peripheral T 
reg population (  12  –  15  ). 
  Despite an extensive literature on the func-
tion of T reg cells in a variety of contexts, little 
is known about the signaling mechanisms in-
volved in their diff  erentiation and maintenance, 
or in the regulation of Foxp3 expression. Several 
papers document defects in signaling molecules 
downstream of the TCR or of co-stimulatory 
receptors that aff  ect the diff  erentiation of both 
the CD4 single-positive (SP) Tconv popula-
tion and the T reg lineage (references   16  –  19  ; 
for review see reference   20  ). On the other hand, 
the identifi  cation of signaling factors specifi  -
cally involved in T reg cell diff  erentiation has 
remained elusive. Diff  erentiation of thymic T 
reg cells, like that of conventional CD4SP thy-
mocytes, is highly dependent on signals ema-
nating from the TCR (  3, 20  ). The repertoire 
of TCRs displayed by T reg cells is distinct 
from that of Tconv cells (  21  –  24  ) and appears to be 
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paralleled at the mRNA level, pointing to an eff  ect on mRNA 
transcription or stability (  Fig. 1 C  ). Furthermore, the observed 
impairment was not caused by a perturbation of the overall 
activation of the cells: similar cell numbers were observed at 
enriched for self-reactive specifi  cities (  22, 25  ). It has been 
proposed that T reg cell diff  erentiation relies on TCRs with 
high affi   nity for MHC  –  self-peptide complexes (  26  –  28  ), al-
though this preference is not necessarily imparted by all high-
affi   nity TCR interactions (  29  –  31  ). Thus, although common 
signaling pathways coordinate the diff  erentiation of Tconv 
and T reg cells, it is not clear whether quantitative or qualitative 
diff  erences account for diff  erentiation into the two lineages. 
  The phenotypic and functional diff  erences between Tconv 
and T reg cells are accompanied by subtle diff  erences in sig-
naling pathways. It has been reported that mature peripheral 
T reg cells, both in humans and mice, display a distinct sig-
naling pattern downstream of the TCR (  32  ) and the IL-2R 
(  33  ) when compared with Tconv cells. Most notably, the 
  activation of the phosphoinositide 3-kinase (PI3K)  –  AKT 
pathway, as indicated by a reduction in AKT phosphorylation, 
was impaired in T reg cells. However, it remains unclear 
what the signifi  cance of this impairment might be in regards 
to T reg diff  erentiation and maintenance. The PI3K  –  AKT 
pathway is often deregulated in immune disease, and expression 
of a constitutively active AKT (AKT*) leads to autoimmu-
nity (  34, 35  ). In this paper, we address the functional con-
sequence of deregulated AKT activity on T reg diff  erentiation 
and Foxp3 expression. Our results describe a unique and sur-
prising eff  ect of AKT in negatively regulating the induction 
of a broad swath of the T reg transcriptional signature, thereby 
identifying a signaling component that selectively aff  ects T reg 
lineage diff  erentiation. 
    RESULTS   
  AKT* impairs de novo Foxp3 induction by TGF-     
  To explore the functional relevance of a hyperactivated PI3K  –
  AKT pathway on T reg cell generation and maintenance, 
we fi  rst used an in vitro system wherein the activation of 
CD4  +  CD25        cells in the presence of TGF-     and IL-2 in-
duces de novo expression of Foxp3 (  10  ). This in vitro system 
is amenable to retroviral gene transfer, facilitating experiments 
aimed at addressing the infl  uence of diverse molecules on 
Foxp3 induction. Purifi  ed CD4  +  CD25        cells were activated 
with anti-CD3/CD28 beads in the presence of TGF-     and 
IL-2 for 24 h, at which time they were retrovirally trans-
duced to express AKT* (a myristoylated allele of AKT), 
which allows its constitutive association with the plasma 
membrane and thereby its constitutive activation (  36  ). In ad-
dition to AKT*, the retroviral vectors encoded either a GFP 
or Thy1.1 marker, which allowed the discrimination be-
tween infected and noninfected cells in the same cultures, the 
latter serving as internal controls (CTRLs). After 72 h, Foxp3 
expression was quantitated by fl  ow cytometry in the infected 
(GFP  +  ) and noninfected (GFP       ) populations. Retrovirus-
mediated expression of AKT* signifi  cantly impaired the in-
duction of Foxp3 by TGF-     (  Fig. 1 A  ; a summary of several 
independent experiments is shown in   Fig. 1 B  ).   This eff  ect 
was specifi  c for and intrinsic to the AKT*-expressing cells, 
with no eff  ect on GFP        uninfected cells in the same cultures. 
The diminished expression of Foxp3 at the protein level was 
    Figure 1.         AKT* impairs de novo induction of Foxp3 by TGF-    .   Naive 
CD4  + CD25       T cells were stimulated with anti-CD3/CD28 beads in the 
presence of TGF-     and IL-2. 24 h after activation, cells were transduced 
with retrovirus encoding either empty vector control (CTRL-RV) or a con-
stitutively active form of AKT (AKT*-RV; A). After a total of 4 d in culture, 
cells were analyzed for intracellular levels of Foxp3 by fl  ow cytometry. 
The percentages of cells positive for Foxp3 are shown. (B) Summary of eight 
independent experiments quantifying Foxp3 expression by fl  ow cytometry 
analysis on the indicated populations. Horizontal lines indicate the mean 
value for each sample. (C) Real-time PCR analysis for Foxp3 mRNA levels 
in the indicated populations. Foxp3 mRNA is normalized to HPRT mRNA. 
Data represent the mean   ±   SEM for three independent experiments. 
(D) The experiment was performed as in A, and cell numbers were determined 
at the end of culture. (E) Naive CD4  + CD25       T cells were stimulated in the 
presence of TGF-     and IL-2. 24 h after activation, cells were transduced 
with retrovirus expressing AKT* or a kinase dead (KD) AKT. Expression of 
Foxp3 was determined after a total of 4 d of culture. The percentages of 
cells positive for Foxp3 are shown. (F) Similar to the experiment in A, except 
that T cells were transduced with retrovirus expressing Bcl-2 or c-myc.     JEM VOL. 205, March 17, 2008 
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blockade of TGF-     signaling or a specifi  c inhibition of Foxp3, 
or whether Foxp3 typifi  ed a gene set targeted by AKT*. 
To address this question, we examined the transcript profi  les 
of conventional CD4  +   T cells cultured in TGF-     and in-
fected by either a retrovirus encoding AKT* or a CTRL 
retrovirus. Total RNA from purifi  ed cell populations was 
purifi  ed, amplifi  ed, and hybridized to M430 2.0 Aff  ymetrix 
whole-genome mouse arrays. Data were normalized using 
the rate monotonic algorithm and were averaged between 
the end of the culture in the presence or absence of AKT* 
(  Fig. 1 D  ). As expected, our AKT* vector did promote cell 
survival in conditions of cytokine deprivation (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20071477/DC1). 
The ability of AKT* to block Foxp3 induction was dependent 
on its kinase activity; a mutant AKT that shares the myris-
toylated modifi  cation found in AKT* but carries an inactivating 
mutation of the kinase domain (KD-AKT(K179M)) (  37  ) was 
unable to aff  ect TGF-      –  mediated Foxp3 induction (  Fig. 1 E  ). 
To the extent tested, the eff  ect of AKT* on Foxp3 induction 
was independent of genetic background, because both NOD 
and B6 mice showed a similar change of downmodulation 
(unpublished data). This eff  ect of AKT* was specifi  c, in that 
no signifi  cant diff  erence in Foxp3 induction was observed 
upon expression of the antiapoptotic molecule Bcl-2 or the 
protooncogene c-Myc, which, as with AKT, have been im-
plicated in T cell survival (  Fig. 1 F  ). 
  To explore the time window during which AKT* could 
exert its inhibitory eff  ect on Foxp3 induction, we transduced 
cells with AKT* at various time points after activation, al-
ways performing the cytofl  uorimetric analysis 3 d later. The 
inhibitory eff  ect was most apparent when AKT* was intro-
duced at early time points after activation (  Fig. 2 A  , top), evi-
dent as both fewer Foxp3  +   cells and a reduction in staining 
intensity in those cells expressing Foxp3.   The reduction in 
the number of Foxp3  +   cells was less severe at later time points, 
although AKT* could still reduce the intensity of Foxp3 ex-
pression in positive cells (  Fig. 2 A  , bottom). The continuous 
presence of TGF-     is necessary to maintain Foxp3 expression 
in such cultures; i.e., Foxp3 begins to disappear within 24 h 
of TGF-     withdrawal (unpublished data) (  38  ). AKT* seems 
to aff  ect this continued   “  confi  rmation  ”   of Foxp3 expression 
as well as the initial induction. 
  To confi  rm this notion, we tested the eff  ect of AKT* 
overexpression on Foxp3 levels in primary T reg cells, whose 
expression of Foxp3 is much more stable in culture (  8  ). T reg 
cells were purifi  ed as CD4  +  CD25  hi  CD62L  hi   and were acti-
vated ex vivo in the presence of TGF-     and IL-2 to allow cell-
cycle entry and, thus, infectivity by retroviruses. Contrary to 
what we had observed for the TGF-      –  induced Foxp3 in Tconv 
cells, the Foxp3 levels in the natural T reg cell cultures were 
refractory to downmodulation upon retroviral expression of 
AKT* (  Fig. 2 B  ). Although transduced T reg cells did tend
 to express slightly lower levels of AKT* overall (as suggested 
by the bicistronic Thy1.1 reporter), this resistance was not 
caused by a lower level of AKT* because the resistance was 
observed at AKT*/Thy1.1 levels that elicited complete in-
hibition in TGF-      –  treated naive cells (  Fig. 2 B  ). Thus, there 
appear to be diff  erences in the molecular circuitry regulating 
Foxp3 induction or maintenance in these two populations, as 
refl  ected by their sensitivity to AKT*. 
  Broad but partial impairment of the T reg transcriptional 
signature by AKT* 
  These fi  ndings raised the question of whether the observed 
inhibition of Foxp3 induction was a consequence of an overall 
    Figure 2.         Differential effect of AKT on established levels of Foxp3.  
(A) Naive CD4  + CD25       T cells were activated as before and transduced 
with retrovirus at the indicated time points. Foxp3 expression was deter-
mined by fl  ow cytometry analysis. The percentages of cells positive for 
Foxp3 are shown. (B) Naive CD4  + CD25       T cells or CD4  + CD25 +   T reg cells 
were stimulated in the presence of TGF-    . T reg cell stimulation was 
done in the presence of 2,000 U IL-2. Cells were transduced with retro-
virus 72 h after activation and analyzed for Foxp3 by fl  ow cytometry 
after an additional 72 h of culture. Data are representative of three or 
more experiments.     568 AKT –  M  TOR AXIS IN T REG DIFFERENTIATION | Haxhinasto et al.
into two distinct clusters of genes diff  ering in their responsive-
ness to AKT*. The genes along the diagonal line (regions R1 
and R3) were equally responsive to TGF-     regardless of the 
presence or absence of AKT*. This group included   Itgae   (en-
coding CD103),   Rgs2  , and   Cpd  . In contrast, for those genes 
that fell within regions R2 or R4, the change in their expres-
sion promoted by TGF-     was reduced or abolished by AKT*. 
As expected,   Foxp3   belonged to this group, which also included 
canonical T reg transcripts such as   Plagl1   or   Nrp1  . Overall, 
AKT* shut down or strongly curtailed     30% of the tran-
scripts induced by TGF-     and     20% of TGF-      –  repressed 
transcripts. Thus, AKT* did not elicit a wholesale block of 
TGF-     signaling nor did it solely shut down   Foxp3  , but rather, 
it targeted a specifi  c subset of genes, one of which was   Foxp3  . 
  Because AKT* aff  ected several genes other than Foxp3, 
we asked what its overall impact was on the transcriptional 
signature that defi  nes T reg cells. We have robustly defi  ned 
elsewhere a consensus   “  T reg signature  ”   deduced from the 
juxtaposition of several T reg and Tconv datasets (  8  ). In   Fig. 4  , 
the changes elicited by AKT* in these T reg signature tran-
scripts are plotted in a volcano plot representation (fold change 
vs. p-value; genes over- and underexpressed in T reg cells are 
shown in red and blue, respectively).   It is clear that AKT* 
  aff  ected a substantial portion of the T reg signature: of 407 
genes overexpressed in T reg cells, 292 were dampened by 
AKT*, whereas 125 out of 196 of the underexpressed genes 
were actually boosted by AKT* in the TGF-      –  induced cul-
tures (P = 4   ×   10      38   and 8.2   ×   10      5   for the up- and down-regu-
lated probes, respectively, according to the       2   test). Notably, 
the induction of several canonical T reg genes, such as   Il2ra  ,   
Ctla-4  ,   Tnfrsf18  , and   Nrp1  , in addition to   Foxp3   itself, was 
reduced by AKT*. Conversely, AKT* increased the expression 
of several genes normally repressed in T reg cells, such as 
  Pde3b   (  6  ). Thus, activated AKT dampens a broad swath of the 
genes whose diff  erential expression characterizes T reg cells. 
  A sizeable component of the T reg signature corresponds 
to genes that respond to IL-2 and T cell activation (  8  ), and 
IL-2 is an essential growth/survival factor for T reg cells (  40  ), 
raising the possibility that the eff  ect of AKT* might be to 
dampen IL-2 and/or activation signals. To this end, we ana-
lyzed the response of a set of IL-2/activation signature genes 
in these cultures (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20071477/DC1): although AKT* did 
aff  ect a substantial proportion of these transcripts, the eff  ect 
was incomplete, indicating that it does not uniformly dampen 
IL-2 signaling. 
  These observations raised the question of whether the 
other aff  ected genes were directly infl  uenced by AKT* or 
were downstream targets of Foxp3 and, as such, mirrored its 
downmodulation. To address this issue, we made use of ex-
isting microarray datasets from cells transduced with Foxp3 
or CTRL retrovirus, which thus defi  ne a   “  Foxp3 signature  ”   
(i.e., the group of genes directly infl  uenced by Foxp3) (  8  ). 
Recently, we have shown that the transcriptional profi  le im-
parted by Foxp3 represents only a subset of the entire T reg 
signature (  8  ). Highlighting those genes that were up-regulated 
three independent replicates. The Multiplot module from 
GenePattern (  39  ) was used for data visualization. 
  Overall, the introduction of AKT* led to a substantial 
number of changes in the overall profi  le of TCR/IL-2/TGF-
      –  activated cells: at an arbitrary fold change threshold of 1.5, 
610 and 1,381 probes were up- and down-regulated by AKT*, 
respectively, far more than in the randomized CTRL dataset 
(  Fig. 3 A  ).   Next, we ascertained more specifi  cally the impact 
AKT* had on the transcript changes imparted by TGF-     (the 
  “  TGF-     signature  ”  ), thereby testing whether the eff  ect on 
Foxp3 was isolated or corresponded to a shutdown of the en-
tire TGF-     signature. We compared the eff  ect of TGF-     (as 
the ratio of expression values in cultures with vs. without 
TGF-    ) in cells that were transduced with AKT* or with the 
CTRL retrovirus. This comparison is displayed in the fold 
change/fold change plot of   Fig. 3 B  , which provides a direct 
comparison of the TGF-     signature in the presence (y axis) 
or absence (x axis) of AKT*. The TGF-     signature partitioned 
    Figure 3.         AKT* specifi  cally targets a subset of the TGF-         signature. 
  (A) Comparison of the expression values of TGF-    – activated  cells  trans-
duced with CTRL or AKT* retrovirus (left) compared with a randomized 
dataset (right). (B) Fold change versus fold change (FcFc) plot comparing 
the TGF-      –  induced signature in AKT*- versus CTRL-transduced cells. Gene 
expression values for cells activated in the absence of TGF-     and  trans-
duced with a CTRL retrovirus were used as the denominator for the Fc. 
Regions R1 and R3 highlight TGF-      –  regulated genes that are refractory 
to AKT* expression. Regions R2 and R4 highlight TGF-    – regulated  genes 
that are affected by AKT* expression.     JEM VOL. 205, March 17, 2008 
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can be observed as early as the CD4  +  CD8  +   double-positive 
(DP) stage of thymocyte diff  erentiation; T reg cells accumu-
late as maturing cells (  41, 42  ). Thus, we chose to infect the 
immediate precursors of DP cells, double-negative (DN) 
thymocytes, and to reimplant these directly into the thymus 
of recipient mice to follow their natural maturation (  Fig. 6 A  ).   
DN thymocytes harvested from congenically marked CD45.1  +   
mice were transduced with a CTRL retrovirus or with one 
expressing AKT*. Both vectors also encode the Thy1.1 
marker for the detection of transduced cells. The transduced 
cells were injected intrathymically into irradiated CD45.2  +   
mice, leading to a wave of diff  erentiation in the following 
10  –  20 d. This system allows diff  erentiation to occur in the 
proper thymic milieu and avoids issues that can occur upon 
expression of the transgene at earlier stages, e.g., in bone 
marrow stem cells. 14 d after injection, we examined the 
ability of the AKT*-transduced thymocytes to diff  erentiate 
into CD4  +  Foxp3  +   cells. Although uninfected (Thy1.1       ) cells 
or Thy1.1  +   cells infected with the CTRL vector gave rise to 
normal proportions of Foxp3  +   cells among CD4SPs, there 
was a striking reduction in the diff  erentiation of Foxp3  +   cells 
from the AKT*-transduced DN precursors (  Fig. 6 B  ; several 
experiments are compiled in   Fig. 6 C  ). On the other hand 
AKT*, expression did not signifi  cantly alter the diff  erentia-
tion of conventional CD4SP populations, as determined from 
(a) the CD4/8 profi  les of Thy1.1  +   cells (  Fig. 6 D  ), (b) the 
  ratio of positively selected Tconv cells relative to DPs (note 
that there is quite some variability between mice for this 
metric, which varies with the continued diff  erentiation poten-
tial of the donor DNs, but that the distribution is similar for 
cells transduced with AKT* and CTRL vectors;   Fig. 6 E  ), 
and (c) the ratio of positively selected CD4- and CD8SPs 
(  Fig. 6 F  ). These results highlight AKT  ’  s selective impact on 
the diff  erentiation of CD4  +  Foxp3  +   T reg cells, with no overt 
(in red) or down-regulated (in blue) by Foxp3 transduction 
(  Fig. 5 A  ) showed that the eff  ect of AKT* could not simply 
be ascribed to the lowering of Foxp3: although some Foxp3-
responsive genes did belong to region R2/R4 of   Fig. 3 B   
(their downmodulation mirroring that of Foxp3), this was 
not the case for all Foxp3-responsive genes.   In addition, many 
genes not responsive to Foxp3 (gray) were part of region R2 as 
well. This distribution argued against a model in which the 
observed downmodulation of R2 genes by AKT* was simply 
the result of a shutdown of Foxp3 expression. For an inde-
pendent confi  rmation of this result, we performed dual-trans-
duction experiments in which Foxp3 levels in AKT*-transduced 
cells were restored by coinfection with a retroviral vector en-
coding FoxP3 (  Fig. 5 B  ). This protocol allowed us to com-
pare mRNA levels for target genes in cells expressing AKT* 
with or without additional FoxP3 (  Fig. 5 C  ). The forced ex-
pression of exogenous Foxp3 restored the levels of Foxp3 
transcripts comparable to those of uninfected cells (  Fig. 5 C  ). 
However, restoration of Foxp3 did not restore the expression 
levels of   Ctla4   or   Gpr83   transcripts (  Fig. 5 C  ), validating the 
conclusion that AKT* aff  ected transcripts of the T reg signa-
ture independent of its eff  ect on Foxp3. 
  Effect of AKT on de novo generation of Foxp3  +  CD4  +   
thymocytes 
  T reg cells are viewed as a distinct lineage that arises in the 
thymus and depends on interactions between the TCR and 
MHC  –  peptide complexes (  20  ). Given the broad eff  ect of AKT* 
on the T reg signature in mature T cells activated in the presence 
of TGF-    , we explored AKT  ’  s impact on the commitment 
of diff  erentiating thymocytes to the T reg lineage in a more 
physiological setting. To this end, it was fi  rst necessary to es-
tablish an experimental system into which we could intro-
duce AKT* at a stage before Foxp3 turn on. Foxp3 expression 
    Figure 4.         AKT* signifi  cantly impairs a subset of T reg signature.   Volcano plot representation (fold change vs. p-value) of the effect of AKT* ex-
pression (ratio of TGF-AKT* to TGF-GFP) on a common T reg signature (red, up; blue, down). Numbers indicate the probes present in either of the regions.     570 AKT –  M  TOR AXIS IN T REG DIFFERENTIATION | Haxhinasto et al.
inhibitory eff  ect of AKT*, although it did not completely 
restore Foxp3 levels to those of uninhibited cells. These results 
identify mTOR and, more specifi  cally, the rapamycin-sensitive 
branch of mTOR complexes as downstream targets of AKT* 
in exerting its eff  ect on Foxp3 induction. On the other hand, 
because the impact of AKT* was not completely abolished 
by rapamycin, additional rapamycin-insensitive pathways may 
also be involved. 
    DISCUSSION   
  Given the critical role of T reg cells in immune tolerance, it 
is important to delineate the signaling pathways that posi-
tively or negatively regulate their diff  erentiation. In this study, 
we investigated the functional consequence that deregulated 
activity of AKT has on Foxp3 induction and T reg specifi  ca-
tion, and identifi  ed AKT as a strong repressor of this process. 
The ability of AKT to inhibit Foxp3 expression was limited 
to the induction phase of Foxp3 both in vivo and in vitro. 
Natural T reg cells with established and stable Foxp3 levels 
were resistant to AKT*  ’  s eff  ect. This diff  erential sensitivity to 
AKT* in natural T reg cells or Foxp3 high-expressing cells 
and the early induced Foxp3  +   cells underscores the signifi  cant 
diff  erences between these states (  8  ) and suggests distinct chro-
matin states as one possibility: a   “  locked-in  ”   state of chroma-
tin at the Foxp3 locus in T reg cells versus a   “  reversible  ”   one 
in the early time points of expression, whether resulting from 
natural commitment to the lineage or from TGF-     induc-
tion. Support for this notion was recently provided by Floess 
et al., who noted complete demethylation of CpG motifs and 
histone modifi  cations within the Foxp3 locus in natural T reg 
cells but not after TGF-     induction (  47  ). 
  The observed impact of AKT* was not attributed to a 
global transcriptional block downstream of TGF-     signaling 
nor to a shutdown of IL2 signaling, but rather it was a specifi  c 
eff  ect on a set of genes that included   Foxp3   and other mem-
bers of the T reg signature, both Foxp3 responsive and Foxp3 
nonresponsive. AKT* infl  uenced the majority of the T reg 
signature genes, although not all of them, such that one can 
readily envision that T reg commitment would be blocked. 
These fi  ndings lend credence to our current view of the 
shaping of the T reg transcriptional landscape as a complex 
interplay of multiple players, with Foxp3 being an important, 
but not the sole, factor (  6  –  8, 48  ). They also implicate AKT 
in molding the T reg signature and provide an important lead 
as to how commitment to the alternative T reg and Tconv 
lineages of CD4  +   cells can occur in the thymus, resulting in 
the diff  erent TCR repertoires (  21  –  24  ): TCRs whose inter-
action with MHC  –  self-peptide complexes result in a balance of 
downstream signals with low AKT activation, relative to 
other signaling pathways, would be those that preferentially 
enter the T reg lineage. In addition, other signaling compo-
nents aff  ecting AKT, such as cytokines, might further modu-
late these signals, perhaps in favored thymic niches. Such 
diff  erential involvement of signaling molecules downstream 
of the TCR and/or CD28 in two diff  erent fates is reminis-
cent of the signaling pathways involved in CD4  +   versus CD8  +   
eff  ect on Tconv diff  erentiation. We are not aware of any other 
element with this property. 
  Signaling from AKT to inhibit Foxp3 induction 
  As we showed in   Fig. 1 E  , the ability of AKT* to block 
Foxp3 induction was dependent on its kinase activity. To 
further explore the signaling pathways involved in T reg dif-
ferentiation, we sought to determine whether this eff  ect was 
mediated via the mammalian target of rapamycin (mTOR) 
pathway. mTOR is a downstream target in the AKT signal-
ing pathway, and recent papers have proposed a link between 
rapamycin and T reg cells both in humans and mice, with ra-
pamycin preferentially sparing T reg cells (  43  –  46  ). We ex-
plored mTOR  ’  s involvement in AKT*  ’  s down-modulatory 
activity by adding rapamycin to cultures of CD3/IL-2/TGF-
      –  triggered CD4  +   cells transduced either by AKT* or CTRL 
retrovirus. By itself, rapamycin did not aff  ect TGF-      –  mediated 
induction of Foxp3 (  Fig. 7  ).   However, rapamycin treatment 
of cells at the time of AKT* transduction did counteract the 
    Figure 5.         Impact of AKT* on Foxp3-dependent and -independent 
genes.   (A) Similar to the experiment in Fig. 3 B, except that genes up-
regulated (red) or down-regulated (blue) by Foxp3 retroviral transduction 
are highlighted. Regions R1, R2, R3, and R4 are outlined. Naive 
CD4  + CD25       T cells were activated as before and transduced with the 
indicated retrovirus. (B) Naive CD4  +   T cells were activated in the presence 
with CD3/CD28 beads in the presence of TGF/IL-2 and transduced with 
AKT*-Thy1.1 and Foxp3-GFP retrovirus. (C) Real-time PCR analysis for 
Foxp3, CTLA-4, and Gpr83 mRNA was performed. Data represent the 
mean   ±   SEM.   JEM VOL. 205, March 17, 2008 
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in the growth and survival of CD4  +   T lymphocytes but not 
in their diff  erentiation (  54  ). Indeed, given the involvement 
of AKT as a positive regulator in CD28 and IL-2R signaling 
(  55  ), both of which are important for Foxp3 expression, our 
fi  ndings may appear somewhat paradoxical. 
  Activation of AKT is lower in T reg than in Tconv cells 
after TCR (  32  ) and IL-2R (  33  ) engagement. Our study sug-
gests that this impairment may not merely be a consequence 
of defective signaling, but that it may serve as an active safe-
guard mechanism to ensure suffi   cient levels of Foxp3 and 
other elements of the T reg signature required for T reg dif-
ferentiation and for the suppressive functions of T reg cells. 
An overly active AKT might override these functions and 
ultimately contribute to immune disease. Indeed, mice express-
ing AKT* present with autoimmune manifestations such as 
multiorgan lymphocytic infi  ltration and autoantibodies (  34, 35  ), 
although no obvious phenotype in CD4  +  CD25  +   T cells has 
T cell lineage commitment or positive and negative selection, 
whereby fi  ne diff  erences in signal strength can account for 
opposing outcomes (  49  –  51  ). These fi  ndings would predict 
a negative impact of CD28 triggering on Foxp3 induction, 
because PI3K is one of the major signaling paths down-
stream of CD28. Indeed, such an eff  ect has been reported, 
where inclusion of anti-CD28 dampened the induction of 
FoxP3 by graded doses of anti-CD3 in a conversion system 
in vitro (  52, 53  ). 
  Despite contextual diff  erences between the natural diff  er-
entiation of thymic T reg cells and the induction of Foxp3 in 
mature T cells by TGF-    , AKT* exerted a similar blocking 
eff  ect in these two populations. These fi  ndings argue for a 
level of similarity for these two populations and place AKT at 
a nexus of signaling pathways whose proper activation has a 
considerable impact on Foxp3 expression and, consequently, 
T reg cell generation. AKT had previously been implicated 
    Figure 6.         AKT* impairs differentiation of CD4  +  Foxp3  +   T cells in vivo.   (A) Schematic of the intrathymic transfer experiments. CD4      CD8       DN 
thymocytes from CD45.1 mice were transduced with retrovirus encoding AKT* or CTRL vector and injected into sublethally irradiated CD45.2 B6 mice. 
2 wk after transfer, donor CD45.1  +   cells were analyzed for their ability to give rise to CD4  + Foxp3 +   cells. (B) Flow cytometry profi  le of the thymocyte popula-
tions gated on donor CD45.1  +   cells transduced either with CTRL or AKT* retrovirus. Intracellular staining for Foxp3 was performed on electronically gated 
CD45.1  + CD4 + Thy1.1    /+   populations. The percentages of cells positive for Foxp3 are shown. (C) Summary of independent experiments (  n   =  6 – 8  mice)  for 
the percentage of CD4  + Foxp3 +   cells gated on donor cells. Horizontal lines indicate the mean. (D) CD4/CD8 profi  le of infected (identifi  ed by a Thy1.1 retro-
virally encoded marker) donor cells. The percentages of cells in the indicated regions are shown. Summary of the ratio of (E) the sum of SP to DP cells and 
(F) of the CD4SP to CD8SP infected cells from various mice. Horizontal lines indicate the mean.     572 AKT –  M  TOR AXIS IN T REG DIFFERENTIATION | Haxhinasto et al.
  MATERIALS AND METHODS 
  Mice.     NOD/LtDOI, BDC2.5/NOD TCR transgenic, C57BL/6, and B6.
SJL-Ptprca Pep3b/BoyJ (CD45.1  +  ) mice were bred in the mouse specifi  c 
pathogen-free animal facility at the Joslin Diabetes Center or were purchased 
from the Jackson Laboratory. All animal experiments approved by the Joslin 
Diabetes Center Institutional Animal Care and Use Committee. 
  Cell purifi  cation.     Naive Tconv cells and T reg cells were harvested from 
spleens and lymph nodes of 4  –  6-wk-old BDC2.5/NOD, NOD, or B6 
mice. After mechanical disassociation and red blood cell lysis, cells were 
  labeled with anti-CD4 (clone RM4-5) PE  –  Texas red or PE  –  Alexa Fluor 610, 
positively enriched with anti-PE beads (Miltenyi Biotec), and sorted on the 
following markers: negative for B220 (clone RA3-6B2), CD8     (clone 5H10), 
CD11b (clone M1/70), and CD69 (clone H1-2F3; all FITC labeled); posi-
tive for CD4; and either positive for CD25 (clone PC61)-allophycocyanin 
(T reg cells) or negative for CD25 (Tconv cells). 
  In vitro activation.     Naive CD4  +  CD25       CD69        T cells were activated 
with anti-CD3  –   and anti-CD28  –  coated beads (Invitrogen) at concentrations 
of one bead per cell in the presence of 20 U/ml of recombinant human IL-2 
(Proleukin; Chiron) with or without 25 ng/ml of recombinant TGF-     
(PeproTech). T reg cells were activated with beads and 2,000 U/ml IL-2 in 
the presence or absence of TGF-    . T cells were cultured for 4 d or longer, 
as indicated in the fi  gures. 
  Retroviral transduction.     293FT cells (Invitrogen) were transfected with 
retroviral expression plasmids (MSCV IRES-Thy1.1/GFP) (  63  ), either 
empty or encoding the constitutively active allele of AKT (  64  ), human Bcl-2 
(  63  ), or human c-myc (  65  ) and the packaging construct pcl-ECO (  66  ) using 
TransIT-293 (Mirus), according to the manufacturer  ’  s instructions. Naive 
CD4  +   T cells were activated in the presence of 20 U/ml IL-2 and 25 ng/ml 
TGF-     and spin infected with retrovirus supernatant at 24 h. Cells were 
subsequently cultured for an additional 72 h for a total in vitro culture of 4 d. 
For time-course experiments, cells were analyzed at the times indicated in 
the fi  gures. 
  Intrathymic transfer of CD4        CD8         T cells.     Thymocytes from 3  –  4-
wk-old CD45.1  +   mice labeled with anti-CD4  –  PE and anti-CD8  –  PE  –  Alexa 
Fluor 610 were depleted with anti-PE beads (Miltenyi Biotec) using AutoMacs 
(Miltenyi Biotec). This allowed   >  90% CD4       CD8        population of thymo-
cytes. DN CD4       CD8        cells were transduced with retrovirus by spin infec-
tion for 1.5 h. After retroviral transduction,     100,000  –  200,000 cells in a 
10-    l volume were injected into each thymic lobe of sublethally irradiated 
(600 rads) C57BL/6 recipients. 
  Gene expression profi  ling.     Sorted cell populations were lysed in TRI  zol   
reagent, and RNA was prepared according to the manufacturer  ’  s instructions 
(Invitrogen). For retroviral cultures, cells were sorted for GFP/Thy1.1 posi-
tivity before RNA processing. RNA amplifi  cation was conducted for two 
rounds using the MessageAmp aRNA kit (Ambion), followed by biotin 
  labeling using the BioArray high yield RNA transcription labeling kit (Enzo 
Life Sciences, Inc.), and purifi  ed using the RNeasy mini kit (QIAGEN). 
The resulting cRNAs were hybridized to M430 2.0 chips (Aff  ymetrix) by 
the Joslin Genomics Core, according to manufacturer  ’  s instructions. All cell 
populations used for the microarray analysis were generated in triplicate and 
individually processed. Raw data were normalized using the rate monotonic 
algorithm implemented in the Expression File Creator module from the 
GenePattern software package (  39  ). Probes were fi  ltered based on minimum 
(  >  20) and maximum (  <  20,000) expression values using the Preprocess Dataset 
module from the GenePattern software. A probe with an expression value 
  <  20 was kept if 3 out of the 64 chips showed a value   >  50. Data were visualized 
using the Multiplot Preprocess and Multiplot modules from the GenePattern 
software. Signature depth and correlation coeffi   cient analyses were conducted 
using S-Plus software (Insightful Corp.). Microarray data have been deposited 
in the Gene Expression Omnibus under accession no.   GSE7596.   
been observed in such mice (  56  ). It has been postulated that 
autoimmunity in this mouse line could in part be caused by 
the resistance of eff  ector cells overexpressing AKT to T reg 
suppression (  57  ). Our study provides additional potential expla-
nations for this phenotype, whereby deregulated expression 
of AKT alters the thymic and perhaps peripheral generation 
of T reg cells. An alternative implication may relate to recent 
data that show that Foxp3 induction by TGF-     can be 
blocked by proinfl  ammatory cytokines such as IL-6, lead-
ing to generation of Th17 cells (  58  ). In light of our fi  ndings 
and given the role of AKT in the IL-6R signaling pathway 
(  59, 60  ), we propose that IL-6 exerts its inhibitory eff  ect in 
an AKT-dependent manner. Moreover, these fi  ndings suggest 
that small molecules that target AKT might prove effi   cacious 
in treatment of autoimmunity and infl  ammation by targeting 
both overreacting eff  ector T cells as well as enhancing T reg 
cell generation. 
  The repression of Foxp3 expression by AKT* required its 
kinase activity and was partly counteracted by rapamycin treat-
ment, adding a potential element to its mechanism of action 
and placing mTOR as a downstream target of AKT. mTOR be-
longs to two distinct complexes, mTORC1 and mTORC2, 
which are diff  erentially sensitive to rapamycin treatment, with 
mTORC1 being the usual target (  61, 62  ). Given the reversal 
of AKT*  ’  s eff  ect by rapamycin, our data suggest that AKT is 
exerting part of its eff  ect via mTORC1. On the other hand, 
the lack of a complete reversal suggests that mTORC2 may 
also partially contribute. These results dovetail and provide a 
possible mechanistic explanation for recent reports document-
ing a relatively protective eff  ect of rapamycin on T reg cells 
(  43  –  46  ). In addition to selectively preserving and expanding 
existing T reg populations, rapamycin treatment may also 
contribute to the generation of new T reg cells by counter-
acting molecular brakes on Foxp3 induction. 
    Figure 7.         Molecular mechanisms of AKT-mediated suppression of 
Foxp3 induction.   Naive  CD4 + CD25       T cells were stimulated in the pres-
ence of TGF-     and IL-2. 24 h after activation, cells were transduced with 
retrovirus and cultured for an additional 72 h in the presence or absence 
of 100 nm rapamycin. Foxp3 expression was determined by fl  ow cytom-
etry. The percentages of cells positive for Foxp3 are shown. Data are rep-
resentative of three or more experiments.     JEM VOL. 205, March 17, 2008 
ARTICLE
573 
regulatory T cell-dependent and -independent mechanisms.       Immunity      .   
  25  :  455    –    471  .    
        16  .   Koonpaew  ,   S.  ,   S.     Shen  ,   L.     Flowers  , and   W.     Zhang  .   2006  .   LAT-mediated 
signaling in CD4  +  CD25  +   regulatory T cell development.       J. Exp. Med.     
  203  :  119    –    129  .    
        17  .   Patton  ,   D.T.  ,   O.A.     Garden  ,   W.P.     Pearce  ,   L.E.     Clough  ,   C.R.     Monk  , 
  E.     Leung  ,   W.C.     Rowan  ,   S.     Sancho  ,   L.S.     Walker  ,   B.     Vanhaesebroeck  , 
and   K.     Okkenhaug  .   2006  .   Cutting edge: the phosphoinositide 3-kinase 
p110 delta is critical for the function of CD4+CD25+Foxp3+ regula-
tory T cells.       J. Immunol.       177  :  6598    –    6602  .   
        18  .   Wohlfert  ,   E.A.  ,   L.     Gorelik  ,   R.     Mittler  ,   R.A.     Flavell  , and   R.B.     Clark  . 
  2006  .   Cutting edge: defi  ciency in the E3 ubiquitin ligase Cbl-b results 
in a multifunctional defect in T cell TGF-beta sensitivity in vitro and 
in vivo.       J. Immunol.       176  :  1316    –    1320  .   
        19  .   Tai  ,   X.  ,   M.     Cowan  ,   L.     Feigenbaum  , and   A.     Singer  .   2005  .   CD28 co-
stimulation of developing thymocytes induces Foxp3 expression and 
regulatory T cell diff  erentiation independently of interleukin 2.       Nat. 
Immunol.       6  :  152    –    162  .    
        20  .   Liston  ,   A.  , and   A.Y.     Rudensky  .   2007  .   Thymic development and 
peripheral homeostasis of regulatory T cells.       Curr. Opin. Immunol.       19  : 
176    –    185  .    
        21  .   Hsieh  ,   C.S.  ,   Y.     Liang  ,   A.J.     Tyznik  ,   S.G.     Self  ,   D.     Liggitt  , and   A.Y.   
  Rudensky  .   2004  .   Recognition of the peripheral self by naturally arising 
CD25+ CD4+ T cell receptors.       Immunity      .     21  :  267    –    277  .    
        22  .   Hsieh  ,   C.S.  ,   Y.     Zheng  ,   Y.     Liang  ,   J.D.     Fontenot  , and   A.Y.     Rudensky  . 
  2006  .   An intersection between the self-reactive regulatory and non-
regulatory T cell receptor repertoires.       Nat. Immunol.       7  :  401    –    410  .    
        23  .   Pacholczyk  ,   R.  ,   H.     Ignatowicz  ,   P.     Kraj  , and   L.     Ignatowicz  .   2006  . 
  Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells.   
    Immunity      .     25  :  249    –    259  .    
        24  .   Wong  ,   J.  ,   R.     Obst  ,   M.     Correia-Neves  ,   G.     Losyev  ,   D.     Mathis  , and   C.   
  Benoist  .   2007  .   Adaptation of TCR repertoires to self-peptides in regula-
tory and nonregulatory CD4+ T cells.       J. Immunol.       178  :  7032    –    7041  .   
        25  .   Picca  ,   C.C.  ,   J.     Larkin     III  ,   A.     Boesteanu  ,   M.A.     Lerman  ,   A.L.     Rankin  , 
and   A.J.     Caton  .   2006  .   Role of TCR specifi  city in CD4+ CD25+ regu-
latory T-cell selection.       Immunol. Rev.       212  :  74    –    85  .    
        26  .   Pacholczyk  ,   R.  ,   P.     Kraj  , and   L.     Ignatowicz  .   2002  .   Peptide specifi  city of 
thymic selection of CD4+CD25+ T cells.       J. Immunol.       168  :  613    –    620  .   
        27  .   Jordan  ,   M.S.  ,   A.     Boesteanu  ,   A.J.     Reed  ,   A.L.     Petrone  ,   A.E.     Holenbeck  , 
  M.A.     Lerman  ,   A.     Naji  , and   A.J.     Caton  .   2001  .   Thymic selection of 
CD4+CD25+ regulatory T cells induced by an agonist self-peptide.   
    Nat. Immunol.       2  :  301    –    306  .    
        28  .   Apostolou  ,   I.  ,   A.     Sarukhan  ,   L.     Klein  , and   H.     von Boehmer  .   2002  . 
  Origin of regulatory T cells with known specifi  city for antigen.       Nat. 
Immunol.       3  :  756    –    763  .   
        29  .   Van Santen  ,   H.M.  ,   C.     Benoist  , and   D.     Mathis  .   2004  .   Number of T reg 
cells that diff  erentiate does not increase upon encounter of agonist ligand 
on thymic epithelial cells.       J. Exp. Med.       200  :  1221    –    1230  .    
        30  .   Liston  ,   A.  ,   S.     Lesage  ,   J.     Wilson  ,   L.     Peltonen  , and   C.C.     Goodnow  .   2003  . 
  Aire regulates negative selection of organ-specifi  c T cells.       Nat. Immunol.     
  4  :  350    –    354  .    
        31  .   Bonasio  ,   R.  ,   M.L.     Scimone  ,   P.     Schaerli  ,   N.     Grabie  ,   A.H.     Lichtman  , and 
  U.H.     von Andrian  .   2006  .   Clonal deletion of thymocytes by circulating 
dendritic cells homing to the thymus.       Nat. Immunol.       7  :  1092    –    1100  .    
        32  .   Crellin  ,   N.K.  ,   R.V.     Garcia  , and   M.K.     Levings  .   2007  .   Altered activation 
of AKT is required for the suppressive function of human CD4+CD25+ 
T regulatory cells.       Blood      .     109  :  2014    –    2022  .    
        33  .   Bensinger  ,   S.J.  ,   P.T.     Walsh  ,   J.     Zhang  ,   M.     Carroll  ,   R.     Parsons  ,   J.C.   
  Rathmell  ,   C.B.     Thompson  ,   M.A.     Burchill  ,   M.A.     Farrar  , and   L.A.   
  Turka  .   2004  .   Distinct IL-2 receptor signaling pattern in CD4+CD25+ 
regulatory T cells.       J. Immunol.       172  :  5287    –    5296  .   
        34  .   Jones  ,   R.G.  ,   M.     Parsons  ,   M.     Bonnard  ,   V.S.     Chan  ,   W.C.     Yeh  ,   J.R.   
  Woodgett  , and   P.S.     Ohashi  .   2000  .   Protein kinase B regulates T lym-
phocyte survival, nuclear factor     B activation, and Bcl-X(L) levels in vivo.   
    J. Exp. Med.       191  :  1721    –    1734  .    
        35  .   Rathmell  ,   J.C.  ,   R.L.     Elstrom  ,   R.M.     Cinalli  , and   C.B.     Thompson  .   2003  . 
  Activated Akt promotes increased resting T cell size, CD28-indepen-
dent T cell growth, and development of autoimmunity and lymphoma.   
    Eur. J. Immunol.       33  :  2223    –    2232  .    
  Online supplemental material.     Fig. S1 shows AKT* promoting T cell 
survival in the absence of growth factors. Fig. S2 shows the eff  ect of AKT* 
on IL-2/activation signature. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20071477/DC1. 
  We thank L. Roser and K. Hattori for assistance with mice; J. LaVecchio and 
G. Buruzula for help with the cytometry; J. Perez, J. Yee, and M. Vokes for microarray 
processing; and J. Hill and M. Feuerer for insightful discussions. 
  This work was supported by grants from the Juvenile Diabetes Research 
Foundation (4-2004-368) and the National Institutes of Health (1R01AI51530), 
Young Chair funds to D. Mathis and C. Benoist, and by Joslin  ’  s National Institute of 
Diabetes and Digestive and Kidney Diseases  –  funded Diabetes and Endocrinology 
Research Center core facilities. S. Haxhinasto was supported by a postdoctoral 
fellowship from the Damon Runyon Cancer Research Foundation. 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   18 July 2007 
Accepted:   22 January 2008 
  REFERENCES 
       1  .   Schwartz  ,   R.H.     2005  .   Natural regulatory T cells and self-tolerance.       Nat. 
Immunol.       6  :  327    –    330  .    
       2  .   Sakaguchi  ,   S.     2004  .   Naturally arising CD4+ regulatory T cells for 
immunologic self-tolerance and negative control of immune responses.   
    Annu. Rev. Immunol.       22  :  531    –    562  .    
       3  .   Fontenot  ,   J.D.  , and   A.Y.     Rudensky  .   2005  .   A well adapted regulatory 
contrivance: regulatory T cell development and the forkhead family 
transcription factor Foxp3.       Nat. Immunol.       6  :  331    –    337  .    
       4  .   Sakaguchi  ,   S.  ,   M.     Ono  ,   R.     Setoguchi  ,   H.     Yagi  ,   S.     Hori  ,   Z.     Fehervari  ,   J.   
  Shimizu  ,   T.     Takahashi  , and   T.     Nomura  .   2006  .   Foxp3+ CD25+ CD4+ 
natural regulatory T cells in dominant self-tolerance and autoimmune 
disease.       Immunol. Rev.       212  :  8    –    27  .    
       5  .   Hori  ,   S.  ,   T.     Nomura  , and   S.     Sakaguchi  .   2003  .   Control of regulatory T cell 
development by the transcription factor Foxp3.       Science      .     299  :  1057    –    1061  .    
       6  .   Gavin  ,  M.A.  ,  J.P.    Rasmussen  ,  J.D.    Fontenot  ,  V.    Vasta  ,  V.C.    Manganiello  , 
  J.A.     Beavo  , and   A.Y.     Rudensky  .   2007  .   Foxp3-dependent programme 
of regulatory T-cell diff  erentiation.       Nature      .     445  :  771    –    775  .    
       7  .   Lin  ,   W.  ,   D.     Haribhai  ,   L.M.     Relland  ,   N.     Truong  ,   M.R.     Carlson  ,   C.B.   
  Williams  , and   T.A.     Chatila  .   2007  .   Regulatory T cell development in 
the absence of functional Foxp3.       Nat. Immunol.       8  :  359    –    368  .    
       8  .   Hill  ,   J.A.  ,   M.     Feuerer  ,   K.     Tash  ,   S.     Haxhinasto  ,   J.     Perez  ,   R.     Melamed  , 
  D.     Mathis  , and   C.     Benoist  .   2007  .   Foxp3 transcription-factor-dependent 
and -independent regulation of the regulatory T cell transcriptional 
signature.       Immunity      .     27  :  786    –    800  .   
       9  .   Kretschmer  ,   K.  ,   I.     Apostolou  ,   E.     Jaeckel  ,   K.     Khazaie  , and   H.     von 
Boehmer  .   2006  .   Making regulatory T cells with defi  ned antigen speci-
fi  city: role in autoimmunity and cancer.       Immunol. Rev.       212  :  163    –    169  .    
        10  .   Chen  ,  W.  ,  W.    Jin  ,  N.    Hardegen  ,  K.J.    Lei  ,  L.    Li  ,  N.    Marinos  ,  G.    McGrady  , 
and   S.M.     Wahl  .   2003  .   Conversion of peripheral CD4  +  CD25       naive T 
cells to CD4  +  CD25  +   regulatory T cells by TGF-     induction of tran-
scription factor Foxp3.       J. Exp. Med.       198  :  1875    –    1886  .    
        11  .   Peng  ,  Y.  ,  Y.    Laouar  ,  M.O.    Li  ,  E.A.    Green  , and  R.A.    Flavell  .  2004  .  TGF-
beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ 
regulatory T cells responsible for protection against diabetes.       Proc. Natl. 
Acad. Sci. USA      .     101  :  4572    –    4577  .   
        12  .   Huber  ,   S.  ,   C.     Schramm  ,   H.A.     Lehr  ,   A.     Mann  ,   S.     Schmitt  ,   C.     Becker  , 
  M.     Protschka  ,   P.R.     Galle  ,   M.F.     Neurath  , and   M.     Blessing  .   2004  . 
  Cutting edge: TGF-beta signaling is required for the in vivo expansion 
and immunosuppressive capacity of regulatory CD4+CD25+ T cells.     
  J. Immunol.       173  :  6526    –    6531  .   
        13  .   Marie  ,   J.C.  ,   D.     Liggitt  , and   A.Y.     Rudensky  .   2006  .   Cellular mechanisms 
of fatal early-onset autoimmunity in mice with the T cell-specifi  c target-
ing of transforming growth factor-beta receptor.       Immunity      .     25  :  441    –    454  .    
        14  .   Li  ,   M.O.  ,   Y.Y.     Wan  , and   R.A.     Flavell  .   2007  .   T cell-produced trans-
forming growth factor-beta1 controls T cell tolerance and regulates 
Th1- and Th17-cell diff  erentiation.       Immunity      .     26  :  579    –    591  .    
        15  .   Li  ,   M.O.  ,   S.     Sanjabi  , and   R.A.     Flavell  .   2006  .   Transforming growth fac-
tor-beta controls development, homeostasis, and tolerance of T cells by 574 AKT –  M  TOR AXIS IN T REG DIFFERENTIATION | Haxhinasto et al.
        36  .   Ahmed  ,  N.N.  ,  H.L.    Grimes  ,  A.    Bellacosa  ,  T.O.    Chan  , and  P.N.    Tsichlis  . 
  1997  .   Transduction of interleukin-2 antiapoptotic and proliferative sig-
nals via Akt protein kinase.       Proc. Natl. Acad. Sci. USA      .     94  :  3627    –    3632  .   
        37  .   Franke  ,   T.F.  ,   S.I.     Yang  ,   T.O.     Chan  ,   K.     Datta  ,   A.     Kazlauskas  ,   D.K.   
  Morrison  ,   D.R.     Kaplan  , and   P.N.     Tsichlis  .   1995  .   The protein kinase 
encoded by the Akt proto-oncogene is a target of the PDGF-activated 
phosphatidylinositol 3-kinase.       Cell      .     81  :  727    –    736  .    
        38  .   Selvaraj  ,   R.K.  , and   T.L.     Geiger  .   2007  .   A kinetic and dynamic analysis of 
Foxp3 induced in T cells by TGF-beta.       J. Immunol.       178  :  7667    –    7677  .   
        39  .   Reich  ,   M.  ,   T.     Liefeld  ,   J.     Gould  ,   J.     Lerner  ,   P.     Tamayo  , and   J.P.     Mesirov  . 
  2006  .   GenePattern 2.0.       Nat. Genet.       38  :  500    –    501  .    
        40  .   Fontenot  ,   J.D.  ,   J.P.     Rasmussen  ,   M.A.     Gavin  , and   A.Y.     Rudensky  . 
  2005  .   A function for interleukin 2 in Foxp3-expressing regulatory T 
cells.       Nat. Immunol.       6  :  1142    –    1151  .    
        41  .   Fontenot  ,   J.D.  ,   J.L.     Dooley  ,   A.G.     Farr  , and   A.Y.     Rudensky  .   2005  . 
  Developmental regulation of Foxp3 expression during ontogeny.       J. Exp. 
Med.       202  :  901    –    906  .    
        42  .   Feuerer  ,   M.  ,   V.     Auyeung  ,   W.     Jiang  ,   P.     Holler  ,   J.     Hill  ,   C.     Campbell  ,   J.   
  Fontenot  ,   D.     Mathis  , and   C.     Benoist  .   2007  .   Enhanced thymic selection 
of FoxP3+ regulatory T cells in the NOD mouse model of autoimmune 
diabetes.       Proc. Natl. Acad. Sci. USA      .     104  :  18181    –    18186  .    
        43  .   Zheng  ,   X.X.  ,   A.     Sanchez-Fueyo  ,   M.     Sho  ,   C.     Domenig  ,   M.H.     Sayegh  , 
and  T.B.    Strom  .  2003  .  Favorably tipping the balance between cytopathic 
and regulatory T cells to create transplantation tolerance.       Immunity      .   
  19  :  503    –    514  .    
        44  .   Battaglia  ,   M.  ,   A.     Stabilini  , and   M.G.     Roncarolo  .   2005  .   Rapamycin 
selectively expands CD4+CD25+FoxP3+ regulatory T cells.       Blood      .   
  105  :  4743    –    4748  .    
        45  .   Strauss  ,   L.  ,   T.L.     Whiteside  ,   A.     Knights  ,   C.     Bergmann  ,   A.     Knuth  , and 
  A.     Zippelius  .   2007  .   Selective survival of naturally occurring human 
CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.    
  J. Immunol.       178  :  320    –    329  .   
        46  .   Qu  ,   Y.  ,   B.     Zhang  ,   L.     Zhao  ,   G.     Liu  ,   H.     Ma  ,   E.     Rao  ,   C.     Zeng  , and 
  Y.     Zhao  .   2007  .   The eff  ect of immunosuppressive drug rapamycin on 
regulatory CD4(+)CD25(+)Foxp3(+)T cells in mice.       Transpl. Immunol.     
  17  :  153    –    161  .    
        47  .   Floess  ,   S.  ,   J.     Freyer  ,   C.     Siewert  ,   U.     Baron  ,   S.     Olek  ,   J.     Polansky  ,   K.   
  Schlawe  ,   H.D.     Chang  ,   T.     Bopp  ,   E.     Schmitt  ,   et al  .   2007  .   Epigenetic 
control of the foxp3 locus in regulatory T cells.       PLoS Biol.       5  :  e38  .    
        48  .   Sugimoto  ,   N.  ,   T.     Oida  ,   K.     Hirota  ,   K.     Nakamura  ,   T.     Nomura  ,   T.   
  Uchiyama  , and   S.     Sakaguchi  .   2006  .   Foxp3-dependent and -independent 
molecules specifi  c for CD25+CD4+ natural regulatory T cells revealed 
by DNA microarray analysis.       Int. Immunol.       18  :  1197    –    1209  .    
        49  .   Alberola-Ila  ,   J.  , and   G.     Hernandez-Hoyos  .   2003  .   The Ras/MAPK cas-
cade and the control of positive selection.       Immunol. Rev.       191  :  79    –    96  .    
        50  .   Hogquist  ,   K.A.     2001  .   Signal strength in thymic selection and lineage 
commitment.       Curr. Opin. Immunol.       13  :  225    –    231  .    
        51  .   Daniels  ,   M.A.  ,   E.     Teixeiro  ,   J.     Gill  ,   B.     Hausmann  ,   D.     Roubaty  ,   K.   
  Holmberg  ,   G.     Werlen  ,   G.A.     Hollander  ,   N.R.     Gascoigne  , and   E.   
  Palmer  .   2006  .   Thymic selection threshold defi  ned by compartmental-
ization of Ras/MAPK signalling.       Nature      .     444  :  724    –    729  .    
      52  .   Kim  ,   J.M.  , and   A.     Rudensky  .   2006  .   The role of the transcription factor 
Foxp3 in the development of regulatory T cells.       Immunol. Rev.       212  :  86    –    98  .     
        53  .   Benson  ,   M.J.  ,   K.     Pino-Lagos  ,   M.     Rosemblatt  , and   R.J.     Noelle  .   2007  . 
  All-trans retinoic acid mediates enhanced T reg cell growth, diff  erentia-
tion, and gut homing in the face of high levels of co-stimulation.       J. Exp. 
Med.       204  :  1765    –    1774  .    
        54  .   Cantrell  ,   D.     2002  .   Protein kinase B (Akt) regulation and function in 
T lymphocytes.       Semin. Immunol.       14  :  19    –    26  .    
        55  .   Kane  ,   L.P.  , and   A.     Weiss  .   2003  .   The PI-3 kinase/Akt pathway and 
T cell activation: pleiotropic pathways downstream of PIP3.       Immunol. Rev.     
  192  :  7    –    20  .    
        56  .   Walsh  ,   P.T.  ,   J.L.     Buckler  ,   J.     Zhang  ,   A.E.     Gelman  ,   N.M.     Dalton  ,   D.K.   
  Taylor  ,   S.J.     Bensinger  ,   W.W.     Hancock  , and   L.A.     Turka  .   2006  .   PTEN 
inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.    
  J. Clin. Invest.       116  :  2521    –    2531  .   
        57  .   Wohlfert  ,   E.A.  , and   R.B.     Clark  .   2007  .     ‘  Vive la Resistance!  ’   - the PI3K-
Akt pathway can determine target sensitivity to regulatory T cell sup-
pression.       Trends Immunol.       28  :  154    –    160  .    
        58  .   Bettelli  ,   E.  ,   M.     Oukka  , and   V.K.     Kuchroo  .   2007  .   T(H)-17 cells in the 
circle of immunity and autoimmunity.       Nat. Immunol.       8  :  345    –    350  .    
        59  .   Heinrich  ,   P.C.  ,   I.     Behrmann  ,   S.     Haan  ,   H.M.     Hermanns  ,   G.     Muller-
Newen  , and   F.     Schaper  .   2003  .   Principles of interleukin (IL)-6-type 
cytokine signalling and its regulation.       Biochem. J.       374  :  1    –    20  .    
        60  .   Hideshima  ,   T.  ,   N.     Nakamura  ,   D.     Chauhan  , and   K.C.     Anderson  .   2001  . 
  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in mul-
tiple myeloma.       Oncogene      .     20  :  5991    –    6000  .    
        61  .   Sabatini  ,   D.M.     2006  .   mTOR and cancer: insights into a complex rela-
tionship.       Nat. Rev. Cancer      .     6  :  729    –    734  .    
        62  .   Bhaskar  ,   P.T.  , and   N.     Hay  .   2007  .   The two TORCs and Akt.       Dev. Cell      .   
  12  :  487    –    502  .    
        63  .   Van Parijs  ,   L.  ,   Y.     Refaeli  ,   J.D.     Lord  ,   B.H.     Nelson  ,   A.K.     Abbas  , and   D.   
  Baltimore  .   1999  .   Uncoupling IL-2 signals that regulate T cell prolifera-
tion, survival, and Fas-mediated activation-induced cell death.       Immunity      .   
  11  :  281    –    288  .    
        64  .   Kelly  ,   E.  ,   A.     Won  ,   Y.     Refaeli  , and   L.     Van Parijs  .   2002  .   IL-2 and related 
cytokines can promote T cell survival by activating AKT.       J. Immunol.     
  168  :  597    –    603  .   
        65  .   Refaeli  ,   Y.  ,   K.A.     Field  ,   B.C.     Turner  ,   A.     Trumpp  , and   J.M.     Bishop  . 
  2005  .   The protooncogene MYC can break B cell tolerance.       Proc. Natl. 
Acad. Sci. USA      .     102  :  4097    –    4102  .   
        66  .   Naviaux  ,   R.K.  ,   E.     Costanzi  ,   M.     Haas  , and   I.M.     Verma  .   1996  .   The pCL 
vector system: rapid production of helper-free, high-titer, recombinant 
retroviruses.       J. Virol.       70  :  5701    –    5705  .                     